The Max Foundation Welcomes New Board Member, Curt Malloy
The Max Foundation is pleased to welcome Curt Malloy as the newest member of our Executive Board. Curt, a fellow advocate for people facing cancer around the world, has been a strong supporter of our work for many years throughout his active engagement in global health.
Curt currently serves as the Chief Operating Officer at Cancer Research And Biostatistics (CRAB) in Seattle, where he leads data management, project management, clinical monitoring, and regulatory. He is a co-leader of CRAB’s Latin America Initiative, which was formed with the intention of providing clinical research training programs for clinical investigators and statisticians in Latin America and identifying clinical research opportunities.
Prior to joining CRAB, Curt was the operational leader for the Fred Hutch Vaccine and Infectious Disease Division, while also serving on the boards of their global research initiatives in South Africa, Uganda, and China. Prior to the Fred Hutch, Curt served for ten years in various leadership positions at the Infectious Disease Research Institute. Curt has a Masters of Public Health from Columbia University School of Public Health and earned a Juris Doctor with a focus on intellectual property from Seattle University School of Law. He is fluent in Spanish and is particularly passionate about Latin America, social and health equity and planetary health.
Pat Garcia-Gonzalez, CEO of The Max Foundation said of Curt’s appointment, “It is well known that The Max Foundation has a strong historical connection to Latin America given that helping families there was the focus of our original mission. Curt has an impressive background that promises to only strengthen our resolve in serving cancer patients in Latin America and across the globe.”
We are thrilled to be able to leverage Curt’s deep experience serving on NGO boards, his expertise in the field of cancer research, and his strong commitment to global health—all to bring dignity and hope to people facing cancer around the world.
The Max Foundation (Max) is a global health nonprofit organization dedicated to accelerating health equity. For more than 25 years, Max has pioneered practical, scalable, high-quality solutions to bring lifesaving treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope. Learn more at www.themaxfoundation.org
Related Articles
Welcoming our New Vice President of Development
The Max Foundation is pleased to announce the hiring of Wilma Comenat as Vice President of Development of The Max Foundation. Wilma has more than 20 years of experience in the nonprofit sector leading development teams and driving major donor fundraising initiatives. Her previous roles include the Associate Executive Director of JDRF Greater Northwest, Regional Director of Lupus Foundation of America, Inc.’s Pacific Northwest region, and Deputy Executive Director of The Leukemia & Lymphoma Society.
Novartis, The Max Foundation, and a young girl who dreamed to be a lawyer
The Max Foundation and Novartis renew their commitment to CML patients
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
SEATTLE, Washington – May 17, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the….
The Max Foundation uses cookies to improve your experience on our site. Please read our Privacy Policy for more information.Dismiss
